Glympse Bio raises more than $46M in Series B round for biosensor technology
The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for the disease.
These are the most active VCs in healthcare since 2012
As investments in life science companies have dipped over the past few years, some investors have scaled back investments or walked away from the sector all together. But based on a tally by investment research firm PitchBook in its 2013 Venture Capital Healthcare Report, several firms have made 10 or more investments in pharmaceutical, medical […]
presented by
The Healthcare Payments Industry Has a Perception Problem
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
Once-monthly HGH replacement therapy gets $25 million VC boost for pediatric trial
For the thousands of adults and children with growth hormone deficiencies, daily injections of replacement hormones are their best bet for preventing the cardiovascular, muscular and metabolic abnormalities associated with the condition. But a few companies are on the hunt for ways to make those injections last longer so that they would require less frequent […]
VC prediction: 2013 will be a good year for medtech deals
A group of investors suggested reverse mergers, licensing strategies and oncology companies during a panel on how to fund a startup company in biotech or medtech. One investor said four forces were combining to make 2013 a great year for medtech.
Relypsa snatches $80M for drug to treat high potassium in kidney disease, diabetes
Patients with kidney disease, diabetes and heart failure can develop elevated potassium levels that can lead to serious complications. Relypsa - which has secured nearly $200 million since its founding - plans to take its drug to phase 3 trials this year.
Drugmaker targets riboswitches to combat antibiotic-resistant diseases
As long-trusted antibiotics encounter increased resistance by the bacterial pathogens they were originally designed to kill, the need for novel anti-infective drug treatments is mounting. One young company has just raised $2.5 million to continue its work on developing treatments for infectious diseases by using bacterial RNA targets called riboswitches. BioRelix Inc. is building a […]
presented by
Antiviral pharma Chimerix raises $45M in series F venture round
Antiviral therapies pharmaceutical company Chimerix has raised $45 million that it will apply toward further clinical development of two compounds, one of which could be used as a defense against biological attacks. The Durham, North Carolina-based company is developing another compound for infections associated with HIV.